Dongsung Pharmaceutical동성제약

Dongsung Pharmaceutical remains loss-making on a trailing basis, and its shares have fallen sharply over the past year.

Dongsung Pharmaceutical reported trailing twelve-month revenue of ₩82.1B to H1 2026, with an operating loss of ₩8.5B and a net loss of ₩12.8B. Revenue has been roughly flat to slightly down over recent years, while losses have widened since 2023. The shares closed at ₩1,306 on 2026-10-20, down 32.9% over one year and about 48% below the 52-week high of ₩2,525.

What stands out

• Trailing operating margin is -10.3% and net margin is -15.6%, versus a small operating profit of ₩0.6B in 2023.
• Cash of ₩37.5B is below borrowings of ₩38.6B, and trailing free cash flow is negative at about -₩25.3B.
• Liabilities are 82.6% of equity, and the stock trades at about 1.4 times book value with no dividend.
• Filings in mid-2026 include two lawsuit-related entries and a designation as a company for unfaithful disclosure, plus a KOSPI listing committee decision to maintain listing.
• Foreign ownership rose from 0.6% to 0.9% over about 60 days, while retail investors were net sellers over the last 20 days.

What to watch

• The next periodic results and whether the operating loss narrows from the trailing figures.
• Outcomes of the pending lawsuits and any follow-up on the unfaithful disclosure designation and listing review.
• Whether the company's cash and borrowings position, and negative free cash flow, need additional financing; the data does not include guidance or forecasts.